Success Metrics

Clinical Success Rate
70.1%

Based on 75 completed trials

Completion Rate
70%(75/107)
Active Trials
41(25%)
Results Posted
89%(67 trials)
Terminated
32(20%)

Phase Distribution

Ph early_phase_1
4
2%
Ph phase_1
58
36%
Ph phase_2
72
44%
Ph phase_3
14
9%
Ph phase_4
1
1%
Ph not_applicable
13
8%

Phase Distribution

62

Early Stage

72

Mid Stage

15

Late Stage

Phase Distribution162 total trials
Early Phase 1First-in-human
4(2.5%)
Phase 1Safety & dosage
58(35.8%)
Phase 2Efficacy & side effects
72(44.4%)
Phase 3Large-scale testing
14(8.6%)
Phase 4Post-market surveillance
1(0.6%)
N/ANon-phased studies
13(8.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

65.8%

75 of 114 finished

Non-Completion Rate

34.2%

39 ended early

Currently Active

41

trials recruiting

Total Trials

163

all time

Status Distribution
Active(42)
Completed(75)
Terminated(39)
Other(7)

Detailed Status

Completed75
Terminated32
Recruiting21
Active, not recruiting20
Withdrawn7
unknown6

Development Timeline

Analytics

Development Status

Total Trials
163
Active
41
Success Rate
70.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (2.5%)
Phase 158 (35.8%)
Phase 272 (44.4%)
Phase 314 (8.6%)
Phase 41 (0.6%)
N/A13 (8.0%)

Trials by Status

not_yet_recruiting11%
terminated3220%
recruiting2113%
unknown64%
suspended11%
withdrawn74%
completed7546%
active_not_recruiting2012%

Recent Activity

Clinical Trials (163)

Showing 20 of 163 trialsScroll for more
NCT05470283Phase 1

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Active Not Recruiting
NCT01857934Phase 2

Therapy for Children With Advanced Stage Neuroblastoma

Completed
NCT04897321Phase 1

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Recruiting
NCT02106988Phase 2

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

Active Not Recruiting
NCT03849651Phase 2

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Active Not Recruiting
NCT04530565Phase 3

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Active Not Recruiting
NCT07257419Phase 1

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Recruiting
NCT04959175Phase 1

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Recruiting
NCT04318678Phase 1

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Recruiting
NCT02436707Phase 2

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Active Not Recruiting
NCT06834282Phase 1

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

Recruiting
NCT06847269Phase 2

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

Recruiting
NCT05436418Phase 1

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Recruiting
NCT00338377Phase 2

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Active Not Recruiting
NCT04904588Phase 2

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Active Not Recruiting
NCT05813327Phase 1

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

Active Not Recruiting
NCT03663933Phase 2

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Active Not Recruiting
NCT06345495Phase 2

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Recruiting
NCT06078696Phase 1

Siplizumab for Sickle Cell Disease Transplant

Terminated
NCT06942039Early Phase 1

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
163